The combination of chemotherapy and immune checkpoint inhibition (ICI) therapy is the
current standard of care for most patients who are fit to undergo treatment for metastatic …

The population of patients with hepatocellular carcinoma (HCC) overlaps to a high degree
with those for chronic kidney disease (CKD) and end-stage renal disease (ESRD). The …

Objectives The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed
chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small …

Optimal survival benefit from different lines of anticancer treatment in advanced nonsmall
cell lung cancer (NSCLC) requires conservation of renal function. We evaluated the …

Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy
for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs …

Over the last few decades pH-sensitive drug delivery systems have been successfully
developed for the treatment of cancers by improving the therapeutical effect. In this study, a …

Background Pemetrexed, a multitargeted antifolate cytotoxic agent, is currently used
primarily in combination with cisplatin for metastatic non-small cell lung cancer and for …

Introduction: Lung cancer still represents the leading cause of death for cancer. About the
70% of diagnosis are in advanced-stage. Non-small-cell lung cancer (NSCLC) represents …

Objectives: To assess the effect of long-term pemetrexed maintenance therapy on patients'
renal function. Methods: In the PARAMOUNT phase III trial (NCT 00789373), pemetrexed …

What is known and objective The use of cisplatin in the treatment of lung carcinoma is
limited by nephrotoxicity. The aim of this study was to determine whether the incidence of …